Development of Pharmacotherapies for the Treatment of Sarcopenia
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Sarcopenia, the associated loss of skeletal muscle mass and strength and impaired physical function seen with aging, is a growing, global public health challenge in need of accepted, proven treatments that address the needs of a broad range of older adults. While exercise, primarily resistance training, and increased dietary protein have been shown to delay and even reverse losses in muscle mass, strength and physical function seen with aging, proven treatments that are accessible globally, cost effective and sustainable by patients are needed. While no drug has yet demonstrated the substantial safety and clinical value needed to be the first pharmacological therapy registered for muscle wasting or sarcopenia, the field is active. Several approaches to treating the muscle loss and subsequent functional decline are being studied in a variety of patient populations across every continent. We provide a review of the leading programs and approaches and available findings from recent studies. In addition, we briefly discuss several related issues needed to facilitate the development of a safe and efficacious pharmacotherapeutic that could be used as part of a treatment plan for older men and women with sarcopenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gait speed and survival in older adults.
Studenski, S. (2011) · JAMA · doi:10.1001/jama.2010.1923 · Cited by 4,558 · cited 1×
“…body of epidemiological and intervention-based literature demonstrating a strong association between decreased gait speed (≥ 0.1 m/s) and future adverse physical, psychological and cognitive status, and health outcomes including falls, hospitalizations, mobility disability and death (89-91).”
InfluentialSarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051 · cited 1×
“Proposed in most consensus statements, grip strength is easy to administer, perform and interpret, does not require motor learning and is relatively inexpensive (32-35, 37, 76).”
Fielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B., Abellan van Kan, G., Andrieu, S., Bauer, J., Breuille, D., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.01.003 · Cited by 3,256 · cited 1×
“Gait speeds of 0.8 m/s and 1.0 m/s over four meters have been recommended to identify older adults at increased risk of functional decline, mobility impairment and adverse health events (32, 34-36, 54, 58).”
InfluentialSelf-citationGoodpaster, B. H., Park, S. W., Harris, T. B., Kritchevsky, S. B., Nevitt, M., Schwartz, A. V., Simonsick, E. M., Tylavsky, F. A., Visser, M., Newman, A. B., et al. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.10.1059 · Cited by 3,083 · cited 1×
“Skeletal muscle weakness is commonly seen with aging and a reduction in skeletal muscle mass, and correlates with mobility disability and other adverse health outcomes (12, 36, 92).”
Guralnik, J. M., Ferrucci, L., Pieper, C. F., Leveille, S. G., Markides, K. S., Ostir, G. V., Studenski, S., Berkman, L. F., & Wallace, R. B. (2000) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/55.4.m221 · Cited by 2,898
Studenski, S. A., Peters, K. W., Alley, D. E., Cawthon, P. M., McLean, R. R., Harris, T. B., Ferrucci, L., Guralnik, J. M., Fragala, M. S., Kenny, A. M., et al. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glu010 · Cited by 2,545 · cited 4×
“This use allows prevalence estimates to be established while considering racial, ethnic and geographical differences (36, 39-44).”
InfluentialSarcopenia: origins and clinical relevance
Rosenberg, I. H. (1997) · The Journal of Nutrition · doi:10.1093/jn/127.5.990s · Cited by 2,399 · cited 1×
“In 1989, Irwin Rosenberg introduced the term “sarcopenia”, to describe the age-associated loss of skeletal muscle mass (31).”
Abellan Van Kan, G., Rolland, Y., Andrieu, S., Bauer, J., Beauchet, O., Bonnefoy, M., Cesari, M., Donini, L. M., Gillette-Guyonnet, S., Inzitari, M., et al. (2009) · The Journal of nutrition, health and aging · doi:10.1007/s12603-009-0246-z · Cited by 2,003
Cruz-Jentoft, A. J., Landi, F., Schneider, S. M., Zuniga, C., Arai, H., Boirie, Y., Chen, L.-K., Fielding, R. A., Martin, F. C., Michel, J.-P., et al. (2014) · Age and Ageing · doi:10.1093/ageing/afu115 · Cited by 1,963
Muscaritoli, M., Anker, S. D., Argilés, J., Aversa, Z., Bauer, J. M., Biolo, G., Boirie, Y., Bosaeus, I., Cederholm, T., Costelli, P., et al. (2010) · Clinical Nutrition · doi:10.1016/j.clnu.2009.12.004 · Cited by 1,732 · cited 2×
“, isometric handgrip strength) and usual gait speed, with a focus on the individual’s quality of life and risk of adverse health events (32-36).”
Cited by
Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment
Chen, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Chou, M.-Y., Iijima, K., Jang, H. C., Kang, L., Kim, M., Kim, S., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.12.012 · Cited by 7,070
Fang, E. F., Xie, C., Schenkel, J. A., Wu, C., Long, Q., Cui, H., Aman, Y., Frank, J., Liao, J., Zou, H., et al. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101174 · Cited by 675
Sarcopenia: A Contemporary Health Problem among Older Adult Populations
Papadopoulou, S. (2020) · Nutrients · doi:10.3390/nu12051293 · Cited by 588
Egan, B., & Sharples, A. P. (2023) · Physiological Reviews · doi:10.1152/physrev.00054.2021 · Cited by 278
Rooks, D., Swan, T., Goswami, B., Filosa, L. A., Bunte, O., Panchaud, N., Coleman, L. A., Miller, R. R., Garcia Garayoa, E., Praestgaard, J., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.20836 · Cited by 177
Self-citationThe prevention of osteoporosis and sarcopenia in older adults
Coll, P. P., Phu, S., Hajjar, S. H., Kirk, B., Duque, G., & Taxel, P. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17043 · Cited by 101
“SARMS and myostatin inhibitors, in particular, demonstrate anabolic effects on muscle mass, although equivocal results on strength and mobility.(70) In short, side effects and effectiveness in comparison to inexpensive lifestyle interventions (resistance exercise and nutrition) have impeded their development.”
BackgroundDioh, W., Tourette, C., Del Signore, S., Daudigny, L., Dupont, P., Balducci, C., Dilda, P. J., Lafont, R., & Veillet, S. (2023) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13195 · Cited by 40
Wei, H., Zhang, J., Cui, K., & Su, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1575580 · Cited by 13
“Drugs that can counteract muscle loss during aging or disease are limited, and various new treatment methods are still in the exploratory stage (22).”
Metadata
- Authors
- Rooks, D., & Roubenoff, R.
- Venue
- The Journal of Frailty & Aging
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 8
- Issue
- 3
- Pages
- 120-130
- ISSN
- 2260-1341 (ISSN-L)
- OpenAlex
- W2941076520
- Cited by
- 46
- References
- 39
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.